Tema Etfs LLC Acquires 27,468 Shares of Genmab A/S Sponsored ADR $GMAB

Tema Etfs LLC raised its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 26.7% in the second quarter, Holdings Channel reports. The fund owned 130,217 shares of the company’s stock after purchasing an additional 27,468 shares during the quarter. Tema Etfs LLC’s holdings in Genmab A/S were worth $2,690,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in GMAB. Headlands Technologies LLC increased its position in Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after purchasing an additional 1,464 shares in the last quarter. CWM LLC boosted its position in Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after buying an additional 603 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after buying an additional 1,070 shares during the last quarter. AlphaCore Capital LLC bought a new stake in shares of Genmab A/S during the second quarter worth $44,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after buying an additional 1,174 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on GMAB shares. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, September 23rd. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. HC Wainwright boosted their price target on Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus price target of $39.75.

Genmab A/S Trading Up 1.1%

Shares of GMAB opened at $32.02 on Friday. The stock’s 50-day moving average price is $30.78 and its two-hundred day moving average price is $25.83. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $33.65. The company has a market capitalization of $20.57 billion, a PE ratio of 13.63, a PEG ratio of 1.65 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. Equities research analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.